Cargando…

Patient preference for second and third line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study

Patient preference is key for medication selection in chronic medical conditions, like type 2 diabetes, where there are many different drugs available. Patient preference balances potential efficacy with potential side effects. As both aspects of drug response can vary markedly between individuals t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shields, Beverley M, Angwin, Catherine D, Shepherd, Maggie H, Britten, Nicky, Jones, Angus G, Sattar, Naveed, Holman, Rury, Pearson, Ewan R, Hattersley, Andrew T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614215/ https://www.ncbi.nlm.nih.gov/pubmed/36477734 http://dx.doi.org/10.1038/s41591-022-02121-6

Ejemplares similares

Patient stratification for determining optimal second and third line therapy for type 2 diabetes: the TriMaster study
por: Shields, Beverley M, et al.
Publicado: (2023)

TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol
por: Angwin, Catherine, et al.
Publicado: (2020)

Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
por: McGovern, Andrew P, et al.
Publicado: (2020)

Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017
por: Dennis, John M., et al.
Publicado: (2019)

Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study
por: Donnelly, Louise A., et al.
Publicado: (2020)

A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin
por: Shepherd, Maggie H., et al.
Publicado: (2018)

Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?
por: Jones, Angus G., et al.
Publicado: (2016)

Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach
por: Dennis, John M, et al.
Publicado: (2018)

Strategies to identify individuals with monogenic diabetes: results of an economic evaluation
por: Peters, Jaime L, et al.
Publicado: (2020)

What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study
por: McGovern, Andrew P., et al.
Publicado: (2019)

Cholecalciferol Supplementation Attenuates Bone Loss in Incident Kidney Transplant Recipients: A Prespecified Secondary Endpoint Analysis of a Randomized Controlled Trial
por: Tsujita, Makoto, et al.
Publicado: (2021)

Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18–50 years
por: Lynam, Anita, et al.
Publicado: (2019)

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
por: Davis, Timothy M. E., et al.
Publicado: (2022)

Mastering the roll: succeeding amidst change means trying new things, failing, and trying more
por: Shea, Gregory P, et al.
Publicado: (2010)

Use of HbA1c in the Identification of Patients with Hyperglycaemia Caused by a Glucokinase Mutation: Observational Case Control Studies
por: Steele, Anna M., et al.
Publicado: (2013)

Mastering communication /
por: Stanton, Nicky, 1944-
Publicado: (2004)

Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial
por: Roberts, Ian, et al.
Publicado: (2012)

Urinary C-Peptide Creatinine Ratio Is a Practical Outpatient Tool for Identifying Hepatocyte Nuclear Factor 1-α/Hepatocyte Nuclear Factor 4-α Maturity-Onset Diabetes of the Young From Long-Duration Type 1 Diabetes
por: Besser, Rachel E.J., et al.
Publicado: (2011)

Practical Classification Guidelines for Diabetes in patients treated with insulin: a cross-sectional study of the accuracy of diabetes diagnosis
por: Hope, Suzy V, et al.
Publicado: (2016)

Identifying Good Responders to Glucose Lowering Therapy in Type 2 Diabetes: Implications for Stratified Medicine
por: Jones, Angus G., et al.
Publicado: (2014)

Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data
por: Dennis, John M, et al.
Publicado: (2019)

Prespecified dose-response analysis for A Very Early Rehabilitation Trial (AVERT)
por: Bernhardt, Julie, et al.
Publicado: (2016)

Recurrent Severe Preschool Wheeze: From Prespecified Diagnostic Labels to Underlying Endotypes
por: Robinson, Polly F. M., et al.
Publicado: (2021)

REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results
por: Olshansky, Brian, et al.
Publicado: (2020)

Identifying routine clinical predictors of non‐adherence to second‐line therapies in type 2 diabetes: A retrospective cohort analysis in a large primary care database
por: Shields, Beverley M., et al.
Publicado: (2019)

Unravelling the Heterogeneity of Non Insulin Dependent Diabetes
por: Pearson, Ewan R, et al.
Publicado: (2000)

Feasibility study to examine discrepancy rates in prespecified and reported outcomes in articles submitted to The BMJ
por: Weston, Jennifer, et al.
Publicado: (2016)

Assumption Checking Before Application of the Prespecified QT Linear Mixed Effect Model is Essential
por: Rekić, Dinko, et al.
Publicado: (2020)

Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19
por: Banerjee, Rahul, et al.
Publicado: (2020)

Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
por: Vardeny, Orly, et al.
Publicado: (2022)

Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine
por: Venkatasubramaniam, Ashwini, et al.
Publicado: (2023)

Maternal hypothyroxinaemia in pregnancy is associated with obesity and adverse maternal metabolic parameters
por: Knight, Bridget A, et al.
Publicado: (2016)

Assessment of the HNF1B Score as a Tool to Select Patients for HNF1B Genetic Testing
por: Clissold, Rhian, et al.
Publicado: (2015)

Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalization
por: Peterson, Ross L., et al.
Publicado: (2019)

Doxylamine-pyridoxine for nausea and vomiting of pregnancy randomized placebo controlled trial: Prespecified analyses and reanalysis
por: Persaud, Navindra, et al.
Publicado: (2018)

Beta-blocker effect on ST-segment: a prespecified analysis of the EARLY-BAMI randomised trial
por: Fabris, Enrico, et al.
Publicado: (2020)

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
por: Beernink, Jelle M., et al.
Publicado: (2023)

Associations between low HDL, sex and cardiovascular risk markers are substantially different in sub-Saharan Africa and the UK: analysis of four population studies
por: Greiner, Rosamund, et al.
Publicado: (2021)

Urine C-Peptide Creatinine Ratio Is a Noninvasive Alternative to the Mixed-Meal Tolerance Test in Children and Adults With Type 1 Diabetes
por: Besser, Rachel E.J., et al.
Publicado: (2011)

Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin
por: Jones, Angus G, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_8i5hh172ssa439pvfpf3cgvtal